Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Curr Mol Med. 2024;24(6):801-812. doi: 10.2174/1566524023666230619123752.
To develop optimal personalized therapy for lung adenocarcinoma (LUAD), potential biomarkers associated with the prognosis are urgently needed. It is unclear what role T Cell Leukemia Homeobox 1 (TLX1) plays in LUAD.
In this study, TLX1's relationship with LUAD was investigated using TCGA database analysis, bioinformatics analysis, and experimental validation.
We examined the expression of TLX1 in pan cancer and LUAD, the relationship between TLX1 expression and clinical features, immune infiltration, its diagnostic and prognostic value, as well as TLX1 related pathways. The analysis included various statistical methods, including the Kaplan-Meier method, Cox regression analysis, GSEA, and immune infiltration analysis. TLX1 expression in LUAD cell lines was validated using qRT-PCR.
In LUAD patients, high expression of TLX1 was associated with T stage (P<0.001). High TLX1 expression was associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.18-2.1; P=0.002). And TLX1 HR: 1.619; 95% CI: 1.012-2.590; P=0.044) was independently correlated with OS in LUAD patients. TLX1 expression was associated with the pathways, including Rho GTPase effectors, DNA repair, TCF dependent signaling in response to WNT, signaling by Nuclear Receptors, signaling by Notch, chromatin-modifying enzymes, ESR-mediated signaling, cellular senescence, and transcriptional regulation by Runx1. TLX1 expression was correlated with aDC, Tcm, and TReg cells. The expression of TLX1 was significantly increased in LUAD cells compared to BEAS-2B cells.
An association between high TLX1 expression and poor survival and immune infiltration was found in LUAD patients. There may be a potential role for TLX1 in diagnosis, prognosis, and immunotherapy for LUAD.
为了为肺腺癌 (LUAD) 制定最佳的个体化治疗方案,迫切需要寻找与预后相关的潜在生物标志物。TLX1 在 LUAD 中的作用尚不清楚。
本研究通过 TCGA 数据库分析、生物信息学分析和实验验证,探讨 TLX1 与 LUAD 的关系。
我们检测了 TLX1 在泛癌和 LUAD 中的表达,TLX1 表达与临床特征、免疫浸润的关系,以及其诊断和预后价值,同时还分析了 TLX1 相关通路。分析包括各种统计方法,包括 Kaplan-Meier 法、Cox 回归分析、GSEA 和免疫浸润分析。使用 qRT-PCR 验证 LUAD 细胞系中 TLX1 的表达。
在 LUAD 患者中,TLX1 的高表达与 T 分期相关(P<0.001)。高 TLX1 表达与总生存期(OS)较差相关(HR:1.57;95%CI:1.18-2.1;P=0.002)。并且 TLX1 在 LUAD 患者中与 OS 独立相关(HR:1.619;95%CI:1.012-2.590;P=0.044)。TLX1 表达与 Rho GTPase 效应物、DNA 修复、TCF 依赖的 WNT 反应信号、核受体信号、Notch 信号、染色质修饰酶、ESR 介导的信号、细胞衰老和 Runx1 转录调控等通路相关。TLX1 表达与 aDC、Tcm 和 TReg 细胞相关。与 BEAS-2B 细胞相比,LUAD 细胞中 TLX1 的表达明显增加。
TLX1 高表达与 LUAD 患者生存不良和免疫浸润相关。TLX1 可能在 LUAD 的诊断、预后和免疫治疗中发挥作用。